Navigation Links
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
Date:2/2/2010

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010, at 10:30 a.m. Eastern time, in the Park South room at the Waldorf Astoria in New York.  The conference is being hosted by the Biotechnology Industry Association.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com.  An archived presentation will be available on the Web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's Web site at www.adventrx.com.  

SOURCE ADVENTRX Pharmaceuticals, Inc.

RELATED LINKS
http://www.adventrx.co
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
2. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
3. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
4. ADVENTRX Pharmaceuticals Announces Closing of Financing
5. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
6. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
7. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
8. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
9. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer").  On 20 May 2013, Royalty Pharma ...
(Date:5/23/2013)... WASHINGTON , May 23, 2013  Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM).  Vanda was honored at the TCM,s 25 ... Bethesda , Maryland.  The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...
(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering.   A portion of the proceeds will be used ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6China Medical Technologies Reports First Fiscal Quarter Financial Results 2China Medical Technologies Reports First Fiscal Quarter Financial Results 3China Medical Technologies Reports First Fiscal Quarter Financial Results 4China Medical Technologies Reports First Fiscal Quarter Financial Results 5China Medical Technologies Reports First Fiscal Quarter Financial Results 6China Medical Technologies Reports First Fiscal Quarter Financial Results 7China Medical Technologies Reports First Fiscal Quarter Financial Results 8China Medical Technologies Reports First Fiscal Quarter Financial Results 9China Medical Technologies Reports First Fiscal Quarter Financial Results 10China Medical Technologies Reports First Fiscal Quarter Financial Results 11China Medical Technologies Reports First Fiscal Quarter Financial Results 12China Medical Technologies Reports First Fiscal Quarter Financial Results 13China Medical Technologies Reports First Fiscal Quarter Financial Results 14China Medical Technologies Reports First Fiscal Quarter Financial Results 15China Medical Technologies Reports First Fiscal Quarter Financial Results 16China Medical Technologies Reports First Fiscal Quarter Financial Results 17China Medical Technologies Reports First Fiscal Quarter Financial Results 18China Medical Technologies Reports First Fiscal Quarter Financial Results 19
(Date:5/24/2013)... KC and Monica Craichy, Founders of ... Their oldest sons, Kyle and Austin Craichy, will be kiteboarding ... several professional kiteboarders. , KC Craichy said he is excited ... come together such that virtually everyone who planned to be ... kite boarders will meet at Matheson Hammock Park and Beach ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...
(Date:5/24/2013)... Denver, CO (PRWEB) May 24, 2013 ... SEO analysis, in partnership with JD Media Surge, a ... , The dental SEO analysis service will focus ... high in the search engines for their competitive keywords. ... the dentists website and recommendations based on what their ...
(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...
(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...
Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2
... on an intensive care ward of a hospital offer a ... the oxygen that keeps them alive when they are unable ... machines can come at a price every year thousands ... number of which are so serious the patient never recovers. ...
... stress-free summer travel, designed for ... your carry-on, ... luscious herbal blends to soften nerves during,flight delays and long waits in ... on vacation, all pre-packed in a zip-lock,tote to pass airport security and ...
... RESTON, Va. and BOSTON, June 3 Most ... interest caused by,pharmaceutical industry marketing. Only 21 of ... Association (AMSA) have strong policies,(those graded A or ... AMSA collaborated with The Prescription Project, an ...
... Language: ,A Novel Diet, by ... Nikki Lang, MD, ... solid, practical and realistic approach to,weight control." -- Nutritionist, Barbara Porcelli, RD, ... Diet,",published by iUniverse, Inc., which offers a unique approach to the eating,disorder ...
... center ... Clinical Trial ... TSX: BMR, TORONTO, June 3 /PRNewswire-FirstCall/ - ... announced that it has received,notification from the United States Food and Drug Administration (FDA) ...
... BALTIMORE, June 3 A new website,( http://www.shofarcoalition.org ... and emotional abuse and neglect of Jewish children. ... specialized services,for children, adolescents, and adults who are ... Shofar Coalition is a Baltimore-based,group, the information on ...
Cached Medicine News:Health News:The breathing lifeline that comes at a price 2Health News:Aromatherapy Luxuries for the Eco-Friendly Traveler 2Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 2Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 3Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 4Health News:Who Knew You Could Learn to Lose Weight by Reading an Enjoyable Novel? 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 3Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 4Health News:New Program/Website Targets Jewish Children, Teens, and Adults Suffering from the Impact of Childhood Maltreatment 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: